Simplify Logo

Full-Time

Head of Communications

Executive Director

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Hardware
Biotechnology
Healthcare

Compensation Overview

$260k - $301kAnnually

+ Equity Awards + Benefits + Learning and Development Opportunities

Senior, Expert

San Carlos, CA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • 12 years of Communications experience with 5 years minimum in a biotech/pharmaceutical company or at a PR/communications agency working with biotech/pharmaceutical clients.
  • Demonstrated experience crafting and executing successful traditional media, social media and internal communications strategies.
  • Experience working with high performing teams and demonstrated ability to collaborate, lead, facilitate, influence and organize across groups and at multiple levels of an organization.
  • Understanding of SEC and FDA regulations impacting communications.
  • Education: bachelor's degree required.
Responsibilities
  • Advance RevMed's corporate visibility and drive understanding of the company's strategy, programs, capabilities and people across priority audiences, internally and externally.
  • Advance capability for external affairs, including media relations, C-suite thought leadership and executive visibility, data/regulatory milestone communications, launch readiness activities, educational campaigns and other public relations engagement tactics/channels.
  • Serve as a company spokesperson with media; develop and build relationships with top-tier business/financial/industry trade press.
  • Oversee development of communications materials, across corporate, pipeline and product communications, including launch readiness materials; materials may include press releases, talking points/Q&A, social/digital content, etc, in collaboration with external agency partners, senior leadership and internal colleagues in Investor Relations, Commercial, Medical Affairs, Patient Advocacy, Legal, and other parts of the organization.
  • In partnership with Investor Relations, plan and prepare for business and scientific events and conferences working closely across various disciplines.
  • Oversee corporate governance (e.g., annual report) and quarterly financial communications, business development communications and CSR/ESG efforts.
  • Prepare company spokespeople for media interviews and other engagements, including training spokespeople, as needed, and ensuring company spokespeople are prepared to address key issues as they emerge.
  • Develop and oversee comprehensive, and compliant corporate branding strategy.
  • Build and execute well organized and consistent internal communications capabilities to support employee engagement, understanding, alignment and inclusion.
  • Collaborate with HR to ensure employee communications are well coordinated and aligned to broader internal and external objectives and messaging.
  • Demonstrate an unwavering commitment to patients, in alignment with patient advocacy function, and oversee efforts on patient-focused communication/engagement programs to drive employee engagement and promote the voice of the patient.
  • Oversee and provide counsel for issues/crisis communications.
  • Oversee social/digital and omnichannel strategy internally and externally.
  • Manage future direct reports and multiple agency partners.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to inhibit the activity of RAS proteins that promote cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

40%

2 year growth

111%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.